Ftse Mib
34.127,62
-0,72%
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
NASDAQ
19.621,68
1,77%
Bitcoin
98.320,40
0,11%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Nevro Corp (NVRO) Nevro Corp (NVRO) Notizie

NVRO

Nevro (NVRO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:NVRO
DataOraFonteTitoloSimboloCompagnia
02/01/202522:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NVRONevro Corp
17/12/202422:30PR Newswire (US)Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08NYSE:NVRONevro Corp
04/12/202422:27Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNYSE:NVRONevro Corp
18/11/202414:30PR Newswire (US)New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral ApproachesNYSE:NVRONevro Corp
14/11/202423:31Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NYSE:NVRONevro Corp
14/11/202423:18Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NYSE:NVRONevro Corp
14/11/202422:11Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVRONevro Corp
12/11/202413:00PR Newswire (US)Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion GloballyNYSE:NVRONevro Corp
11/11/202422:05PR Newswire (US)Nevro Reports Third-Quarter 2024 Financial ResultsNYSE:NVRONevro Corp
29/10/202421:30PR Newswire (US)New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation TherapyNYSE:NVRONevro Corp
10/10/202422:45PR Newswire (US)Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024NYSE:NVRONevro Corp
24/09/202414:00PR Newswire (US)Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord StimulationNYSE:NVRONevro Corp
28/08/202422:15PR Newswire (US)Nevro to Present at Wells Fargo 2024 Healthcare ConferenceNYSE:NVRONevro Corp
06/08/202422:48Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:NVRONevro Corp
06/08/202422:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:NVRONevro Corp
06/08/202422:05PR Newswire (US)Nevro Reports Second-Quarter 2024 Financial ResultsNYSE:NVRONevro Corp
09/07/202422:15PR Newswire (US)Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024NYSE:NVRONevro Corp
11/06/202422:15PR Newswire (US)Nevro to Present at Truist Securities MedTech ConferenceNYSE:NVRONevro Corp
17/05/202422:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:NVRONevro Corp
09/05/202422:05PR Newswire (US)Nevro to Present at BofA Securities 2024 Healthcare ConferenceNYSE:NVRONevro Corp
07/05/202422:05PR Newswire (US)Nevro Reports First-Quarter 2024 Financial ResultsNYSE:NVRONevro Corp
17/04/202414:30PR Newswire (US)Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024NYSE:NVRONevro Corp
28/02/202422:10PR Newswire (US)Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewNYSE:NVRONevro Corp
21/02/202422:06PR Newswire (US)Nevro Enters Into Cooperation Agreement With Engaged CapitalNYSE:NVRONevro Corp
21/02/202422:05PR Newswire (US)Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsNYSE:NVRONevro Corp
14/02/202421:47Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNYSE:NVRONevro Corp
01/02/202422:30PR Newswire (US)Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic NeuropathyNYSE:NVRONevro Corp
29/01/202422:30PR Newswire (US)Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024NYSE:NVRONevro Corp
18/01/202422:15PR Newswire (US)Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic NeuropathyNYSE:NVRONevro Corp
17/01/202422:15PR Newswire (US)Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual MeetingNYSE:NVRONevro Corp
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:NVRO

La tua Cronologia

EU
AUCJL
Amundi null
NYSE
AXTA
Axalta Coating Systems
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network